KR101832501B1 - Composition for anti-dandruff - Google Patents
Composition for anti-dandruff Download PDFInfo
- Publication number
- KR101832501B1 KR101832501B1 KR1020120013888A KR20120013888A KR101832501B1 KR 101832501 B1 KR101832501 B1 KR 101832501B1 KR 1020120013888 A KR1020120013888 A KR 1020120013888A KR 20120013888 A KR20120013888 A KR 20120013888A KR 101832501 B1 KR101832501 B1 KR 101832501B1
- Authority
- KR
- South Korea
- Prior art keywords
- dandruff
- extract
- composition
- scalp
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 65
- 210000004761 scalp Anatomy 0.000 claims abstract description 31
- -1 t Species 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 210000004209 hair Anatomy 0.000 claims description 18
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 14
- 229940097275 indigo Drugs 0.000 claims description 14
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 241000238424 Crustacea Species 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 241001105098 Angelica keiskei Species 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 244000184734 Pyrus japonica Species 0.000 abstract description 4
- 241000208422 Rhododendron Species 0.000 abstract description 2
- 230000008447 perception Effects 0.000 abstract 1
- 230000009471 action Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 241000222336 Ganoderma Species 0.000 description 4
- 241001291474 Malassezia globosa Species 0.000 description 4
- 241001291477 Malassezia restricta Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 description 2
- 229960005265 selenium sulfide Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- CNHZRRBWLMSLDX-WNHLAMKZSA-N 2''O-acetylplatycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNHZRRBWLMSLDX-WNHLAMKZSA-N 0.000 description 1
- SDKXNUPDGQJUHA-ACRKBEDHSA-N 3''O-acetylplatycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](OC(C)=O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SDKXNUPDGQJUHA-ACRKBEDHSA-N 0.000 description 1
- PXQNZQURQNZGKZ-UHFFFAOYSA-N 3-O-beta-Laminaribiosyl-platycodin-D(2) Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O PXQNZQURQNZGKZ-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 241001116477 Adenophora triphylla Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000725156 Aglaonema modestum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000703121 Campanula rotundifolia Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 1
- JUIYKRQGQJORHH-ZIIOQTAFSA-N Rhamnazin 3-rutinoside Natural products O(C[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](OC2=C(c3cc(OC)c(O)cc3)Oc3c(c(O)cc(OC)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 JUIYKRQGQJORHH-ZIIOQTAFSA-N 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 241000267040 Sasa borealis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- DSHSDWSTXKYPEQ-DAANLMTCSA-N [(2s,3r,4s,5s)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4ar,5r,6ar,6as,6br,8ar,9r,10r,11s,12ar,14bs)-10-[(2r,3 Polymers O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DSHSDWSTXKYPEQ-DAANLMTCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 229940118308 colloid sulfur Drugs 0.000 description 1
- 230000000056 copulatory effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical class CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- IVDSKBGNLNNRFN-UHFFFAOYSA-N platycodin A Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(OC(=O)C)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O IVDSKBGNLNNRFN-UHFFFAOYSA-N 0.000 description 1
- CGAIRBPQYHFIOM-UHFFFAOYSA-N platycodin C Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(OC(=O)C)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O CGAIRBPQYHFIOM-UHFFFAOYSA-N 0.000 description 1
- PXQNZQURQNZGKZ-MXNHKPIDSA-N platycodin D2 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PXQNZQURQNZGKZ-MXNHKPIDSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- DSHSDWSTXKYPEQ-UDVDIBAVSA-N polygalacin D2 Polymers O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DSHSDWSTXKYPEQ-UDVDIBAVSA-N 0.000 description 1
- DSHSDWSTXKYPEQ-UHFFFAOYSA-N polygalacin-D2 Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O DSHSDWSTXKYPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000338 selenium disulfide Inorganic materials 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 인동꽃 추출물을 포함하고 길경, 사삼, 지각 및 산죽잎으로부터 선택되는 1종 이상의 추출물을 포함하는 항비듬용 두피 조성물에 관한 것으로, 본 발명의 조성물은 부작용이 없으면서도, 우수한 항비듬 효과를 나타낸다는 장점이 있다.The present invention relates to an anti-dandruff scalp composition comprising an extract of Rhododendron japonica and at least one extract selected from the group consisting of Gilchuan, Samam, Perception and Sanjuk Leaves. The composition of the present invention has excellent anti-dandruff effect . ≪ / RTI >
Description
본 발명은 인동꽃 추출물을 포함하고 길경, 사삼, 지각 및 산죽잎으로부터 선택되는 1종 이상의 추출물을 포함하는 항비듬용 두피 조성물에 관한 것으로, 특히 천연 식물인 인동꽃, 길경, 사삼, 산죽잎 또는 지각 추출물을 유효성분으로 포함하여 부작용이 없으면서도, 그 효과의 우수성이 실험적으로 입증된 항비듬용 두피 조성물에 관한 것이다.The present invention relates to an anti-dandruff scalp composition comprising an indigo flower extract and at least one extract selected from the group consisting of Gilchuan, Sambrook, The present invention relates to an anti-dandruff scalp composition which has been experimentally proved to be superior in its effect even when there is no side effect including a crust extract as an active ingredient.
비듬은 사전적 의미로 피발 두부(被髮頭部)의 피부 표면에서 자연히 떨어져 나오는 각질(角質)에 지방이나 먼지가 묻어서 생긴 때의 일종이다. Dandruff is a kind of dermatologist who has fat or dust on the keratin that comes off naturally from the skin surface of the hair of the head of the papilloma.
두피는 모발과 같이 새로운 두피가 생성되어 치환되는데, 모발에 비하여 빠른 속도로 약 1달에 한번 정도로 새로운 세포로 치환된다. 건강한 두피의 경우 각질층 (Horny Layer or Stratum corneum)의 세포는 눈에 보이지 않을 정도의 작은 크기로 떨어져 나가면서 새로운 각질세포로 빠르게 치환된다. 그러나, 각질세포가 과다하게 생성되어 각질세포 덩어리가 눈에 보일 정도로 뭉쳐 두피에서 벗겨지는 것을 비듬이라 한다.As scalp, new scalp is created and replaced like hair. It replaces new cells about once a month at a faster rate than hair. In a healthy scalp, the cells of the horny layer (or stratum corneum) are quickly replaced with new keratinocytes as they collapse to an invisible small size. However, it is called dandruff that the excess keratinocyte is formed so that the mass of keratinocyte clusters so that the keratinocyte clusters are visible and peeled off from the scalp.
여성보다는 남성에서 비듬이 많고, 10살 아래의 아이에게 비듬은 거의 없으나, 유아, 아동을 거치면서 증가하여 사춘기에는 매우 일반적으로 발생한다.Dandruff is more common in males than females, and dandruff is rare in children under 10 years, but it increases during infancy and childhood and occurs very commonly in puberty.
이와 같은 비듬과 같이 증세가 유사하고, 같은 두피에서 발생하여 많이 혼돈하게 되는 비듬과 유사한 건선 (psoriasis)과 지루성 피부염 (Seborrheic dermatitis)은 비듬과는 차이가 있다. 우선 비듬은 건선이나 지루성 피부염과는 달리 단지 두피에서만 발생하는 것에 비하여, 건선은 몸 전체에서 발생 가능하며, 지루성 피부염은 신체 중에서 지루성인 부위에서 많이 발생하며, 특히 얼굴에서 가장 많이 볼 수 있다. 건선과 지루성 피부염은 홍반 등의 염증 반응을 동반하지만, 비듬은 염증 반응과는 전혀 무관한 것이다.Psoriasis and seborrheic dermatitis, similar to dandruff, are similar to dandruff, which is similar to dandruff and is very confusing. First, psoriasis can occur throughout the body, whereas dandruff can occur only in the scalp, unlike psoriasis or seborrheic dermatitis. Seborrheic dermatitis occurs most often in the seborrheic areas of the body, especially in the face. Psoriasis and seborrheic dermatitis are accompanied by inflammatory reactions such as erythema, but dandruff is completely independent of the inflammatory response.
이러한 비듬 발생 원인으로는 여러 가지가 있으며, 우선 피지분비의 증가가 있다. 비듬의 주요 원인균으로 추측되어지는 Malassezia 속의 미생물은 지방산을 사용하여 피부에서 필요한 외인성(exogenous)의 지방산을 결핍시킨다. 따라서, 필요한 지방산을 얻기 위해 피지 생산을 높여 분비하게 되고, 이러한 메카니즘 의해 피지가 과도하게 분비되고, 이로 인해 각질 세포가 덩어리로 뭉쳐져서 비듬이 생기는 것으로 알려져 있다. 또한 리파아제 효소에 의해 피지가 분해되어 생긴 자유 지방산에 의한 작용도 원인 중에 하나로 추측할 수 있다. 피부에서 분비되어 있는 피지가 리파아제 효소에 의해 분해되어 자유 지방산을 생성하는데, 이 자유 지방산은 직접적 또는 간접적으로 두피 자극 및 피부 손상을 유도하여 비듬을 생기게 하는 것으로 알려져 있다. 이러한 과정을 지방분해 메카니즘이라고 한다.There are various causes of the occurrence of dandruff, first, there is an increase in sebum secretion. Malassezia which is presumed to be the main cause of dandruff Microorganisms in the genus use fatty acids to exfoliate the exogenous fatty acids required by the skin. Thus, in order to obtain the required fatty acid, sebum production is increased and secreted, and sebum is excessively secreted by such a mechanism, and keratinocytes are clustered into a mass, resulting in dandruff. In addition, the action of free fatty acids produced by lipase degradation by lipase enzyme can be considered as one of the causes. The sebum secreted from the skin is decomposed by the lipase enzyme to form free fatty acid, which is known to directly or indirectly induce scalp irritation and skin damage, resulting in dandruff. This process is called a fat-splitting mechanism.
또한 가장 주요한 요인으로서 미생물에 의한 작용을 들 수 있다. 주로 Malassezia restricta나 Malassezia globosa같은 비듬 유발균들이 비듬 보유 환자에서 정상 두피에서 발견되는 양에 비해서 2배 정도 많이 발견된다.The most important factor is the action by microorganisms. mainly Malassezia restricta or Malassezia globosa is found to be twice as many as the amount found in normal scalp in patients with dandruff.
또 한 가지 원인으로서 두피의 세포분열 증가를 들 수 있다. 이는 효소와 지방산에 의한 것이 아닌 대사작용 이상에 의한 세포 분열의 증가를 의미한다.Another cause of scalp And increased cell division. This means an increase in cell division due to metabolic abnormalities not caused by enzymes and fatty acids.
또 다른 원인으로는 비정상적인 각질화 (Parakeratosis : 부전각화) 부전각화효소에 의해 발생하는 것으로 각질세포가 과다 생산되어, 표피의 각질층에서 세포핵이 남아 있고, 각화가 불완전한 채로 끝나 비듬이 발생한다.Another cause is abnormal keratinization (Parakeratosis), which is caused by the enzyme keratinization, and the keratin cells are overproduced, leaving nuclei in the stratum corneum of the epidermis, resulting in incomplete keratinization and dandruff.
그 밖에 스트레스, 환경적 요인, 음식물적 요인, 유전적 요인등 여러 가지 요인들이 있다.Other factors include stress, environmental factors, food factors, and genetic factors.
이러한 여러 가지 원인에도 불구하고 현재 시판중인 항비듬용 제품은 대부분 비듬균의 성장을 저해하여 비듬을 완화시키는 방법을 접근하고, 이러한 목적으로 항균 성분들을 사용하고 있다.Despite these various causes, currently available anti-dandruff products tend to inhibit the growth of dandruff and approach to mitigate dandruff and use antibacterial components for this purpose.
이러한 성분들에는 아연피리치온(Zinc Pyrithione), 셀레니움설파이드(Selenium Sulfide), 피록톤올아민(Piroctone Olamine), 클림바졸(Cilmbazole), 살리실산(Salicylic acid), 케토코나졸(Ketoconazole), 코올타르(Coal Tar), 코르티코스테로이드(Corticosteroid), 콜로이드설퍼(Colloid Sulfur), 셀레니움 디설파이드(Selenium disulfide) 등이 있다.These ingredients include, but are not limited to, Zinc Pyrithione, Selenium Sulfide, Piroctone Olamine, Cilmbazole, Salicylic acid, Ketoconazole, Coal Tar Corticosteroids, Colloid Sulfur, Selenium disulfide, and the like.
그러나, 이들 항비듬제들 대부분은 강한 살균력을 특징으로 하는 물질로서 대부분 부작용이나 독성이 있어 일정량 이상을 사용하기 어려우며, 이에 따라 국내 약사관계 법령집에 기재된 원료에 있어서도 그 함량을 규제하고 있다.However, most of these anti-dandruff agents are characterized by strong sterilizing power, and most of them have side effects or toxicity, so that it is difficult to use more than a certain amount. Therefore, the content is also regulated in the raw materials described in the laws and regulations of domestic pharmacists.
따라서 본 발명에서는 독성이나 부작용을 최소화하기 위하여, 천연 한약재를 대상으로 항비듬 조성물을 제조하였으며, 항균 기능에 국한된 항비듬 효과가 아닌 한방의 원리에 의한 두피 정상화에 의하여, 건강한 두피를 만들어서 근본적으로 비듬 발생을 완화한다.Therefore, in order to minimize toxicity and side effects, the present invention has been made to prepare anti-dandruff compositions for natural herbal medicines. By normalizing the scalp by the principle of oriental medicine not anti-dandruff effect limited to antibacterial function, Mitigate the occurrence.
이러한 비듬발생 원인을 한방적 관점에서 살펴보면 체내의 열에 의하여 피부가 건조해지며 이로 인하여 각질세포가 피부에서 들뜨게 되어 발생하는 것으로 보며, 열에 의하여 균의 생장에 더 좋은 조건이 되어 이를 촉진하는 것으로 본다.From the viewpoint of oriental medicine, it is considered that the skin is dried by heat in the body and the keratinocyte is excited by the skin, and it is considered that it is a better condition for the growth of the germ by heat.
따라서 이러한 한방적 관점에서 비듬의 치료는 열을 식혀주고, 염증을 완하하며, 부위를 씻어주는 것으로 접근한다.Therefore, treatment of dandruff from this herbal viewpoint approaches to cool the fever, relieve inflammation, and wash the area.
이상과 같은 내용에 착안하여, 본 발명자는 각각의 원인에 효과적인 천연 추출물을 선정하였고, 이러한 추출물들의 조합에 의해 우수한 항비듬력을 나타내는 것을 발견하여 본 발명을 완성하였다.In view of the above, the inventors of the present invention have selected effective natural extracts for each cause and found that they exhibit excellent dandruff performance by combination of these extracts, thus completing the present invention.
본 발명의 목적은 인동꽃 추출물을 포함하고 길경, 사삼, 지각 및 산죽잎으로부터 선택되는 1종 이상의 추출물을 포함하는 부작용이 없으면서도 항비듬 효과가 우수한 항비듬용 두피 조성물을 제공하는 것이다.It is an object of the present invention to provide an anti-dandruff scalp composition which is excellent in anti-dandruff effect without side effects including an indigo flower extract and at least one extract selected from leaves of Ganoderma,
본 발명의 일 구체예에서, 인동꽃 추출물; 및 길경, 사삼, 지각 및 산죽잎으로부터 선택되는 1종 이상의 추출물을 포함하는 항비듬용 두피 조성물을 제공한다.In one embodiment of the present invention, an indigo flower extract; And an extract of at least one selected from the group consisting of Ganoderma, Ganoderma, Sephadex and Ganoderma lucidum.
본 발명의 일 구체예에서, 상기 추출물은 추출용매를 사용하여 유기용매를 통한 추출물 또는 물을 이용한 수추출물, 중탕 추출물 및 초임계추출물로부터 선택되는 1종 이상의 추출물을 포함하고, 상기 추출용매는 정제수; 메탄올, 에탄올, 1-프로판올, 이소프로필알코올 또는 부탄올의 저급 알코올; 글리세롤, 에틸렌글리콜, 프로필렌 글리콜 또는 1, 3-부틸렌 글리콜의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로로메탄 또는 클로로포름의 탄화수소계 용매를 포함하나, 이들로 제한되는 것은 아니다.In one embodiment of the present invention, the extract comprises at least one extract selected from water extracts, water extracts and supercritical extracts using an extractant or water through an organic solvent using an extraction solvent, ; Lower alcohols of methanol, ethanol, 1-propanol, isopropyl alcohol or butanol; Polyhydric alcohols such as glycerol, ethylene glycol, propylene glycol or 1, 3-butylene glycol; And hydrocarbon-based solvents such as petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane or chloroform.
또한, 추출시, 상기 추출용매의 첨가량은 천연물 재료의 건조 중량 1g 당 5~20 ㎖로 함이 바람직하다. 천연물 재료의 추출 조건은 실온에서 1~7일간 침적 추출하거나 50~95℃의 가온 조건에서 1~5시간 정도 추출하는 방법 등이 사용될 수 있으나 이들로 제한되는 것은 아니며 당업계에 사용되는 일반적인 용매추출방법이 모두 적용될 수 있다. 실온에서 상기 천연물들을 70% 에탄올에 소정의 시간 동안 냉침시켜 추출하고, 여과하는 방법으로 추출물을 수득하여 사용할 수 있다.In addition, when extracting, the amount of the extraction solvent added is preferably 5 to 20 ml per 1 g of the dry weight of the natural material. Extraction conditions of the natural materials may include extraction by immersion for 1 to 7 days at room temperature or extraction for 1 to 5 hours at a temperature of 50 to 95 ° C, but not limited thereto, All of the methods can be applied. The natural products can be extracted by cooling the extracts with 70% ethanol for a predetermined period of time at room temperature and filtering the extract.
본 발명의 일 구체예에서, 상기 인동꽃 추출물, 길경, 사삼, 지각 또는 산죽잎의 추출물은 조성물의 총 중량에 대하여 0.0001~50 중량%를 포함하고, 바람직하게는 0.001~20 중량%를 포함한다. 0.001 중량% 미만에서는 항비듬 효과가 미미하고, 50 중량%보다 높은 농도에서는 제형상 적용이 어려워서 나타나는 효과에 비해 불편함이 크게 나타나 바람직하지 않기 때문이다.In one embodiment of the present invention, the extract of Rhododendron japonica, Gamgang, Samyang, Crataegi or Crataegi leaves contains 0.0001 to 50% by weight, preferably 0.001 to 20% by weight based on the total weight of the composition . If the amount is less than 0.001% by weight, the anti-dandruff effect is insignificant, and when the concentration is higher than 50% by weight, the application of the form is difficult, which is disadvantageous.
본 발명의 일 구체예에서, 상기 조성물을 포함하는 외용액제, 크림제, 연고제, 페이스트, 에어로솔제, 겔제, 또는 왁스제 형태의 두피에 적용시킬 수 있는 두피 국소 도포형 항비듬제를 제공한다.In one embodiment of the present invention, there is provided a scalp topical dandruff agent which can be applied to scalp in the form of a solution, cream, ointment, paste, aerosol, gel, or wax containing a composition as described above.
본 발명의 일 구체예에서, 상기 조성물을 포함하는 샴푸, 린스, 앰플, 또는 트리트먼트 형태의 모발에 적용시킬 수 있는 화장료 조성물을 제공한다.In one embodiment of the present invention, there is provided a cosmetic composition which can be applied to hair in the form of a shampoo, rinse, ampoule, or treatment containing the composition.
또한, 본 발명의 조성물에는, 모발의 특성을 고려하여, 부가적인 기능 부여를 위해 보습제, 모근 강화제, 모발 보수제, 두피 보호제, 청량제, 대전방지제 등의 보조 성분들을 첨가할 수 있고, 이들은 통상의 것들을 사용할 수 있으나, 이에 한정되는 것은 아니다. 이들 보조 성분은 주성분의 효과를 방해하지 않고, 제형을 유지하기 위한 범위 내에서 사용할 수 있다. In addition, the composition of the present invention may be supplemented with auxiliary ingredients such as a moisturizing agent, a hair firming agent, a hair restorer, a scalpel, a refreshing agent and an antistatic agent for imparting additional functions in consideration of the characteristics of the hair, But is not limited thereto. These auxiliary ingredients can be used within the range to maintain the formulation without interfering with the effect of the active ingredient.
본 발명에 따른 조성물의 사용에 의해 우수한 항비듬 효과가 있고, 상기 조성물에 함유된 천연 추출물의 효과에 의하여 두피의 열을 식히고, 염증을 가라앉히며, 두피를 깨끗하게 하며, 비정상적인 과각화에 의한 비듬 형성을 완화하므로서 두피를 정상화시켜서 우수한 항비듬 효과를 나타낸다는 장점이 있다.The use of the composition according to the present invention has an excellent anti-dandruff effect, and the effect of the natural extract contained in the composition makes it possible to cool the scalp, soothe the inflammation, clean the scalp, And thus it has an advantage of exhibiting excellent anti-dandruff effect by normalizing the scalp.
본 발명을 더욱 상세히 설명하면 다음과 같다. The present invention will be described in more detail as follows.
본 발명의 주요 구성성분인 인동꽃은 인동덩굴 (Lonicera japonica Thunberg)의 꽃봉오리이다. 이 약은 작은 막대 내지 깔때기 모양을 한 꽃봉오리와 흔히 입술모양의 꽃이 섞여 있고, 길이 15~35mm이다. 바깥면은 백색 내지 황갈색을 나타내며 확대경으로 보면 엷은 갈색의 털이 밀생하였고 5개의 수술이 있다. 인동꽃은 특이한 방향이 있고 맛은 떫고 조금 달다. 약리 작용으로는 항균작용, 항바이러스작용, 항진균작용, 수렴작용, 이뇨작용 등이 있다. 주요 효능은 청열해독(淸熱解毒)으로 열독 병증을 열을 내리고 독을 없애는 방법으로 치료하는 것을 의미한다. 주요 성분으로는 이노시톨(inositol), 루테올린(luteolin), 타닌(tannin)이 있다.The rhizome of the present invention is a flower bud of Lonicera japonica Thunberg. This medicine is a small rod or funnel-shaped bud, often mixed with lips and flowers, 15 ~ 35mm in length. The outer surface is white to yellowish brown. The magnifying glass shows a light brown hairs and five stamens. The flower of an indigo flower has an unusual direction, the taste is sweet and a little sweet. Pharmacological actions include antimicrobial action, antiviral action, antifungal action, convergent action, and diuretic action. The main efficacy is to treat fever by treating fever with fever and poisoning with fever (detoxification). The major components are inositol, luteolin, and tannin.
본 발명의 또 다른 주요 구성성분인 길경은 길경근이라고도 하며, 도라지(Platycodon grandiflorum A. De Candolle)의 뿌리를 그대로 또는 주피를 제거한 것이다. 이 약은 불규칙하게 가늘고 긴 방추형 내지 원추형이며, 때때로 가지가 달린 것이 있고 바깥면은 회갈색, 담갈색 또는 백색이다. 주근은 길이 10~15cm, 지금1~3cm이다. 냄새가 약간 있고 맛은 처음에는 없으나 나중에는 아리고 쓰다. 이 약은 회갈색이며 단단하고 길이 5cm, 지름 1cm이상이며 사포닌의 함량이 많은 것이어야 한다. 약리 작용으로는 거담작용, 진해작용, 항백선균작용(抗白癬菌作用) 등이 있고, 효능은 선폐거담(宣肺祛痰), 배농(排膿) 작용이 있다. 주요 성분은 플라티코딘 A(Platycodin A), 플라티코딘 C, 플라티코딘 D1, 플라티코딘 D2, 폴리갈라신 D1(Polygalacin D1), 폴리갈라신 D2, 베튤린(Betulin), 이눌린(Inulin), 피토스테롤(Phytosterol)이 있다.Another major constituent of the present invention is Gilyeong, which is also called Giligyeong, and is obtained by removing the root of Platycodon grandiflorum A. De Candolle as it is. The drug is irregularly elongated, fusiform or conical, sometimes with branches, and the outer surface is grayish brown, pale brown or white. The main muscle is 10 ~ 15cm long, now 1 ~ 3cm. There is a slight smell and there is no taste at first, but later it is scratched. This medicine is gray-brown, hard, 5cm in length, 1cm in diameter, and should have a high saponin content. The pharmacological action is the gadam action, the vinegar action, the anti-piceal germ action (anti-bacillus bacteria action), and the efficacy has the action goddock (肺 祛 痰), drainage (drainage) action. The major components are Platycodin A, Platycodin C, Platycodin D1, Platycodin D2, Polygalacin D1, Polygalacin D2, Betulin, Inulin ), And phytosterol.
본 발명의 또 다른 주요 구성성분인 사삼은 Adenophora triphylla var. japonica Hara 및 동속식물(도라지과 Campanulaceae)의 뿌리이다. 우리 나라 각처의 산지에 나는 다년초 식물로서, 키 50-100cm이며, 전체에 털이 있고 뿌리는 흰색이고 굵다. 근생엽은 잎자루가 길고, 거의 원형. 경생엽은 호생 또는 윤생, 타원형 또는 난형, 잎자루는 짧거나 없고, 양 끝이 날카로우며, 가장자리는 겹톱니가 있다. 性은 미한(微寒)하고, 맛은 쓰다. 주요 성분은 정유와 사포닌이며, 효능은 윤폐지해(潤肺止咳), 양위생진(養胃生津), 거담(祛痰), 구갈(口渴)이다.Another major constituent of the present invention, the ginseng, is Adenophora triphylla var. It is the root of the japonica Hara and the copulatory plants (bellflower and Campanulaceae). It is a perennial plant, 50-100cm tall, with hairs all over and roots white and thick. Leaflet is long, almost circular. Leaves are horn or ovate, elliptical or ovate, petiole is short or absent, both ends are sharp, and edges have double sawtooth. Sex is faint, taste is bitter. The main ingredients are essential oil and saponin, and the efficacy is the abolition of gyeoljeoljeong (肺血 止血), Yang Hyosungjin (养胃 生 津), goddam (祛痰), gogal (口渴) is.
본 발명의 또 다른 주요 구성성분인 지각은 광귤나무(Citrus aurantium Linne)의 채 익지 않은 열매를 둘로 쪼갠 것이다. 이 약은 방향이 있으며 맛은 쓰로 약간 시다. 주요 성분은 리모넨(Limonene), 리날룰(Linalool), 폰시린(poncirin), 나린진(naringin)이며, 성질은 평하다.Another major constituent of the present invention is the crust cut into unripe fruit of Citrus aurantium Linne in two. This medicine has a certain direction and the taste is a little bit wider. The main ingredients are limonene, linalool, poncirin, naringin, and the properties are fair.
본 발명의 또 다른 주요 구성성분인 산죽잎은 (Sasa boreails(Hack.) Mak.) 산죽(조릿대)의 잎으로서 예로부터 불가사의한 약효가 있다고 알려져 있다. 약효는 청열, 해독, 항암효과가 있으며, 고혈압, 당뇨, 만성간염, 위궤양에 효과가 있는 것으로 알려져 있다.
Another major constituent of the present invention, Saja boreails (Hack.) Mak., Is a leaf of Sasa borealis (Sasa boreales). It has been known to be effective against hypertension, diabetes, chronic hepatitis and gastric ulcer.
이하, 본 발명을 하기 실시예 및 실험예에 의해 더욱 구체적으로 설명한다. 그러나 이들 실시예 및 실험예는 본 발명의 이해를 돕기 위한 것일 뿐, 본 발명의 범위를 제한하고자 하는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, these examples and experimental examples are provided only for the understanding of the present invention, and are not intended to limit the scope of the present invention.
실시예Example 1. 추출물의 제조 1. Preparation of extract
먼저 인동꽃과 길경, 사삼, 지각, 산죽잎을 불순물을 걸러낸 후, 대한약전에 수재된 기준에 따른 에탄올과 정제수를 약 4 ~ 10 배량 가하여 5 일간 실온에서 냉침하였다. 추출된 원액을 와트만 #3 여과지를 사용하여 여과하고, 여과된 추출물을 감압농축기를 이용하여 45 ℃에서 추출 용매를 완전히 증발시켜 건조된 추출물을 제조하였다.
First, the impurities were filtered out from alfalfa flowers, Gyungyang, Samshan, crustacean, and ganjuk leaf, and about 4 to 10 times of ethanol and purified water according to the criteria of the Korean Pharmacopoeia were added thereto, followed by cooling at room temperature for 5 days. The extracted extract was filtered using Wattman # 3 filter paper, and the extracted extract was completely evaporated at 45 ° C using a vacuum concentrator to prepare a dried extract.
실시예Example 2 내지 4. 2 to 4. 항비듬Antidandruff 조성물의 제조 Preparation of composition
상기 실시예 1에서 제조된 인동꽃과 길경, 사삼, 지각, 산죽잎추출물로부터 하기 표 1에 기재된 구성으로 당업계에 공지된 통상의 방법에 따라 항비듬 조성물을 제조하였다.
The anti-dandruff compositions were prepared according to the conventional methods known in the art from the indomethacin flowers, Gyungyang, Samshan, crustacean, and mountain juice leaf extracts prepared in Example 1 as described in the following Table 1.
비교예Comparative Example 1 내지 4 1 to 4
비교예 1 내지 4는 하기 표 1에 기재된 바와 같이 인동꽃과 길경, 사삼, 지각, 산죽잎 추출물을 모두 포함하지 않는 구성으로 당업계에 공지된 통상의 방법에 따라 항비듬 조성물을 제조하였다.Comparative Examples 1 to 4 were prepared according to the conventional methods known in the art in a composition not containing both indigo flower and Gakugei, ginseng, crust, and mountain juice leaf extract as shown in Table 1 below.
실험예Experimental Example 1. 비듬균을 이용한 1. Using dandruff 항비듬균력Antisstimulus 평가 evaluation
항비듬 효과 연구에 주로 이용되는 실험법으로는 비듬균인 Malassezia globosa, Malassezia restricta 등 비듬을 유발하는 것으로 알려진 진균을 대상으로 항비듬균력 평가를 실시하는 방법과 비듬 환자를 대상으로 조성물의 사용 전후를 비교하여 항비듬균력 평가를 실시하는 방법이 사용되고 있다.The anti-dandruff effect was evaluated by comparing the anti-dandruff power of dandruff, Malassezia globosa, and Malassezia restricta, which are known to cause dandruff, A method of evaluating antidinocyclosis is used.
본 발명에서는 실시예 1에 따라 얻어진 인동꽃, 길경, 사삼, 지각, 산죽잎 추출물을 사용하여 비듬균인 Malassezia globosa, Malassezia restricta를 대상으로 항비듬균력 시험을 실시하였다.In the present invention, anti-dandruff test was performed on dandruff, Malassezia globosa and Malassezia restricta, using indocyanine flower, Gyungyang, samsang, crustacea, and mountain juice leaf extract obtained according to Example 1.
Malassezia globosa, Malassezia restricta는 비듬을 유발하는 것으로 알려진 균종으로, 두피의 피지를 이용하는 과정에서 생산된 부산물 및 균자체가 비듬을 일으키는 것으로 알려져 있다. 따라서 두 균종에 대한 항균력을 평가함으로서 항비듬력을 유추해 볼 수 있다.Malassezia globosa and Malassezia restricta are known to induce dandruff. It is known that by-products and fungi produced during the process of using scalp sebum cause dandruff. Therefore, anti-dandruff can be deduced by evaluating the antimicrobial activity against two species.
두 균종을 Modified dixon agar 배지에 접종 후, 일정 농도로 희석한 시료 20ul를 종이디스크에 떨어뜨리고 30℃에서 3~7일간 배양한 후 생성된 클리어존(clear zone)의 크기를 측정하여 항비듬균력을 측정하였다.After inoculation of the two species into the modified dixon agar medium, 20ul of the diluted sample was dropped on a paper disc and cultured at 30 ° C for 3 to 7 days. The size of the clear zone generated was measured to determine the anticlastic activity Were measured.
각 시료는 비교예 1 및 실시예 2에 따라 제조된 시료를 실험에 사용하였다. 각 시료는 10%의 농도로 희석하여 실험에 사용하였다. 그 결과를 각각 하기 표 2에 나타내었다. Samples prepared according to Comparative Example 1 and Example 2 were used in the experiments. Each sample was diluted to a concentration of 10% and used in the experiment. The results are shown in Table 2 below.
표 2의 결과에서 보여지듯이 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 함유한 실시예 2는 항비듬균력을 나타내는 클리어존이 넓게 나타난 것을 확인할 수 있었으며, 추출물을 함유하지 않은 비교예 1은 항비듬균력을 나타내지 않는 것을 확인할 수 있었다.As shown in the results of Table 2, it was confirmed that the clear zone showing the anti-dandruff power was widely exhibited in Example 2 containing Rhodophylla and Gakyung, Samam, It was confirmed that it did not show anti-dandruff power.
상기 결과로 보아 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 함유한 시료는 항비듬균력을 나타냄으로서 항비듬 효과를 나타냄을 확인할 수 있었다.
As a result, it was confirmed that the samples containing indigo flower and Gakyung, Samam, crust, and japanese leaf extract showed anti - dandruff power and exhibited anti - dandruff effect.
실험예Experimental Example 2. 비듬환자 대상 임상 시험 2. Clinical trial for dandruff patients
비듬환자에 대한 효과를 알아보기 위하여 비듬이 있는 환자를 대상으로 임상 시험을 실시하였다.To investigate the effect of dandruff on patients, clinical trials were conducted on patients with dandruff.
피험자로서 만 20세 이상의 성인 남녀중 비듬이 있는 사람을 대상으로 하여, 각각의 시료당 5명씩 1일 1회 샴푸를 하는 방식으로 실시하였으며, 최소 2주에서 1개월까지 실시하였다.As subjects, subjects who had dandruff among adult men and women over 20 years old were shampooed once a day for 5 persons per each sample, and they were performed for at least 2 weeks to 1 month.
효과의 판정은 비듬 병변 부위의 사진 판정 및 자각 증상 개선 정도를 다음의 평가 척도에 따라 5 단계로 평가하였다 (표 3). 그 결과를 하기 표 4에 나타내었다.The results of the evaluation of the effects of the dermatological lesions were evaluated in five steps according to the following evaluation scale (Table 3). The results are shown in Table 4 below.
표 4의 결과에서 보여지듯이 추출물을 포함하지 않은 비교예 1에서 보다 추출물을 포함한 실시예 2 내지 4에서 육안 판정 및 자각 증상에서 모두 우수한 항비듬력을 나타냄을 확인하였다.As shown in the results of Table 4, it was confirmed that Examples 2 to 4 containing the extract showed superior dandruff power in visual examination and subjective symptoms than in Comparative Example 1 which did not contain the extract.
또한, 임상시험에서의 사용기간 동안 대상자 전원에게서 어떠한 부작용도 발견되지 않아 인체에도 안전한 것으로 나타났다.In addition, during the period of use in clinical trials, no adverse effects were found in all subjects and it was found to be safe for human body.
이상의 결과를 종합하여 보면, 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 함유한 시료는 이를 포함하지 않는 시료에 비하여 항비듬균 시험에서 더 우수한 항비듬균력을 나타내었으며, 또한 비듬 환자를 대상으로 한 임상시험에서도 매우 우수한 효과를 나타내었다.Compared with the samples containing the extracts of Indong flower, Gyungyang, Samgam, Crustacea, and Sanjukji leaf, the anti-dandruff test showed better anti-dandruff power than the samples containing no extract, In one clinical trial, it showed very good effect.
따라서, 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 함유하는 조성물은 인체에 인전하면서도 우수한 항비듬 효과를 나타냄을 알 수 있다.
Therefore, it can be seen that a composition containing Rhodiola giganta and Gakyung, Samam, Crataegi, and Yamana japonica leaf extract exhibits excellent anti-dandruff effect while being attracted to human body.
실시예Example 5 내지 7. 샴푸 형태의 모발 및 두피 적용 조성물의 제조 5 to 7. Preparation of hair and scalp application compositions in shampoo form
상기 실시예 1에 따라 수득한 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 포함하는 샴푸 형태의 모발 및 두피 적용 조성물을 제조하였다.A shampoo type hair and scalp application composition containing an indigo flower and a Gakyung, a ginseng, a crust, and a mountain juice leaf extract obtained according to Example 1 was prepared.
실시예Example 8 내지 9. 린스 형태의 모발 및 두피 적용 조성물의 제조 8 to 9. Preparation of rinse-type hair and scalp application composition
상기 실시예 1에 따라 수득한 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 포함하는 린스 형태의 모발 및 두피 적용 조성물을 제조하였다.A rinse-type hair and scalp application composition containing indomethacin, ganoderma, ginseng, crust, and mountain juice leaf extract obtained according to Example 1 was prepared.
실시예Example 10. 앰플 형태의 모발 및 두피 적용 조성물의 제조 10. Preparation of compositions for application to hair and scalp in ampoule form
상기 실시예 1에 따라 수득한 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 포함하는 앰플 형태의 모발 및 두피 적용 조성물을 제조하였다.An ampoule-shaped hair and scalp application composition containing an indigo flower, Gakgye, Samgam, crust, and mountain juice leaf extract obtained according to Example 1 was prepared.
실시예Example 11 내지 12. 11-12. 토닉tonic 형태의 모발 및 두피 적용 조성물의 제조 Of hair and scalp application composition
상기 실시예 1에 따라 수득한 인동꽃 및 길경, 사삼, 지각, 산죽잎 추출물을 포함하는 토닉 형태의 모발 및 두피 적용 조성물을 제조하였다.A tonic hair and scalp application composition comprising the indomethacin, the ginseng, the ginseng, the crust, and the mountain juice leaf extract obtained according to Example 1 was prepared.
지금까지 예시적인 실시 태양을 참조하여 본 발명을 기술하여 왔지만, 본 발명의 속하는 기술 분야의 당업자는 본 발명의 범주를 벗어나지 않고서도 다양한 변화를 실시할 수 있으며 그의 요소들을 등가물로 대체할 수 있음을 알 수 있을 것이다. 또한, 본 발명의 본질적인 범주를 벗어나지 않고서도 많은 변형을 실시하여 특정 상황 및 재료를 본 발명의 교시내용에 채용할 수 있다. 따라서, 본 발명이 본 발명을 실시하는데 계획된 최상의 양식으로서 개시된 특정 실시 태양으로 국한되는 것이 아니며, 본 발명이 첨부된 특허청구의 범위에 속하는 모든 실시 태양을 포함하는 것으로 해석되어야 한다. While the present invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. You will know. In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention be construed as including all embodiments falling within the scope of the appended claims.
Claims (7)
상기 추출물은 추출용매를 사용하여 유기용매를 통한 추출물 또는 물을 이용한 수추출물, 중탕 추출물 및 초임계추출물로부터 선택되는 1종 이상의 추출물을 포함하는 것을 특징으로 하는 항비듬용 두피 조성물.The method according to claim 1,
Wherein the extract comprises at least one extract selected from water extracts, water extracts, and supercritical extracts using an extracting solvent or water using an extracting solvent using an extracting solvent.
상기 추출용매는 정제수; 메탄올, 에탄올, 1-프로판올, 이소프로필알코올 또는 부탄올의 저급 알코올; 글리세롤, 에틸렌글리콜, 프로필렌 글리콜 또는 1, 3-부틸렌 글리콜의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로로메탄 또는 클로로포름의 탄화수소계 용매를 포함하는 것을 특징으로 하는 항비듬용 두피 조성물.3. The method of claim 2,
The extraction solvent may be purified water; Lower alcohols of methanol, ethanol, 1-propanol, isopropyl alcohol or butanol; Polyhydric alcohols such as glycerol, ethylene glycol, propylene glycol or 1, 3-butylene glycol; And a hydrocarbon-based solvent of petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane or chloroform.
상기 인동꽃 추출물, 길경, 사삼, 지각 또는 산죽잎의 추출물은 조성물의 총 중량에 대하여 0.0001~50 중량%를 포함하는 것을 특징으로 하는 항비듬용 두피 조성물.The method according to claim 1,
Wherein the extract of Angelica keiskei koidz., Gakkyu, Seisham, Seikaku or Yamaku leaves contains 0.0001 ~ 50 wt.% Based on the total weight of the composition.
상기 인동꽃 추출물, 길경, 사삼, 지각 또는 산죽잎의 추출물은 조성물의 총 중량에 대하여 0.001~20 중량%를 포함하는 것을 특징으로 하는 항비듬용 두피 조성물.The method according to claim 1,
Wherein the extract of Angelica keiskei koidz., Gakkyu, Samyang, Crataegi, or Seishi leaves comprises 0.001 to 20% by weight based on the total weight of the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120013888A KR101832501B1 (en) | 2012-02-10 | 2012-02-10 | Composition for anti-dandruff |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120013888A KR101832501B1 (en) | 2012-02-10 | 2012-02-10 | Composition for anti-dandruff |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130092260A KR20130092260A (en) | 2013-08-20 |
KR101832501B1 true KR101832501B1 (en) | 2018-02-26 |
Family
ID=49217145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120013888A Expired - Fee Related KR101832501B1 (en) | 2012-02-10 | 2012-02-10 | Composition for anti-dandruff |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101832501B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210144391A (en) | 2020-05-22 | 2021-11-30 | (주)동방비앤에이치 | Hair cosmetics material for removing dandruff and preventing scalp trouble, and manufacturing apparatus of hair cosmetics material for manufacturing the hair cosmetics material for removing dandruff and preventing scalp trouble |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102163976B1 (en) * | 2018-12-14 | 2021-03-23 | 재단법인 전라북도생물산업진흥원 | trifoliate orange extracted by Tincture How to make odor reducing animal shampoo using this |
CN110179706A (en) * | 2019-05-22 | 2019-08-30 | 上海璞萃生物科技有限公司 | A kind of Lonicera Japonica extracting solution and preparation method thereof with whitening function |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006347904A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
-
2012
- 2012-02-10 KR KR1020120013888A patent/KR101832501B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006347904A (en) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210144391A (en) | 2020-05-22 | 2021-11-30 | (주)동방비앤에이치 | Hair cosmetics material for removing dandruff and preventing scalp trouble, and manufacturing apparatus of hair cosmetics material for manufacturing the hair cosmetics material for removing dandruff and preventing scalp trouble |
Also Published As
Publication number | Publication date |
---|---|
KR20130092260A (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105555285B (en) | For promoting the composition of hair tonic and hair growth | |
KR101336362B1 (en) | Cosmetic composition | |
KR102576693B1 (en) | Cosmetic composition comprising infused oils of calendular and mixed extracts of plants for moisturizing skin | |
KR20160082138A (en) | Composition for improving skin condition comprising extract of hydrangea serrata | |
JP2011088845A (en) | Involucrin expression inhibitor | |
KR101832501B1 (en) | Composition for anti-dandruff | |
KR102323101B1 (en) | Composition for improving hair and scalp condition coprising extract of hydrangea serrata | |
CN105687056B (en) | A kind of Chinese medicine shampoo and preparation method thereof that suitable puerpera uses | |
KR102025859B1 (en) | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same | |
KR20170137465A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR100777542B1 (en) | Anti-dandruff hair cosmetic composition | |
KR20100011176A (en) | Natural and oriental herbs complex with anti-hairloss and hair growth stimulating effects | |
JP4754834B2 (en) | Cosmetics | |
KR100681699B1 (en) | Hair cosmetic composition for treating dandruff, containing mung bean extract as an active ingredient | |
KR20150145577A (en) | Cosmetic composition for scalp and hair | |
KR101692910B1 (en) | Composition for relieving seborrheic dermatitis and method for manufacturing thereof | |
KR20210100133A (en) | Red mouth extract for dandruff treatment | |
KR102575518B1 (en) | Cosmetic composition for preventing hair loss or dandruff comprising herbal extracts | |
KR102503191B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102275550B1 (en) | Composition for improving hair and scalp condition coprising extract of colored barley | |
KR102337422B1 (en) | Cosmetic composition comprising jojoba oil for skin calming care and skin trouble improvement, and preparing method the same | |
KR102682301B1 (en) | Hair Cosmetic Composition | |
KR102076002B1 (en) | Composition for improving hair and scalp condition coprising extract of korean fir | |
KR20150052907A (en) | Cosmetic composition for Improving Skin Moisturization Comprising the mixed extract of Peach blossom, Sophora japonica flower, Rhubarb and Clove buds as active ingredient | |
KR20130104261A (en) | Cosmetic composition for moisturizing effect on the skin containing the mixture of citron seed extract, seaweed extract and linseed extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120210 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170104 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20120210 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170907 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180213 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180220 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180220 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20211203 |